Biotechnology News and Research

RSS

PharmaVentures announces global expansion of PharmaDeals Agreements

PharmaVentures, the company behind the PharmaDeals(R) range of business information, announced today the expansion of its PharmaDeals Agreements coverage that includes exclusive interviews with deal makers around the world. The announcement follows major enhancement of its dedicated, market leading platform delivering deal data and information to the pharmaceutical and biotechnology sector.

19 Aug 2010

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has completed the nine (9) doses to be administered to the three (3) vanguard patients in the low dose group of its phase II cervical dysplasia clinical trial study.

19 Aug 2010

Cognition Therapeutics receives grant to develop small-molecule drug candidate for Alzheimer's disease

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $228,668 to Cognition Therapeutics (CogRx) to develop small molecule drugs that block the action of the toxic "oligomers" thought responsible for Alzheimer's disease (AD).

19 Aug 2010

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

ImmunoGen, Inc., a biotechnology company that develops antibody-based targeted anticancer products, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (formerly IMGN901) product candidate when used for the treatment of small-cell lung cancer (SCLC).

19 Aug 2010

Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS

Bolder BioTechnology, Inc. today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $600,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to demonstrate the feasibility of using our novel, long-acting IL-11 analog to accelerate platelet recovery and improve survival in a mouse model of Acute Radiation Syndrome (ARS).

18 Aug 2010

Regenicin acquires worldwide exclusive license to know-how technology

Regenicin, Inc., a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement").

18 Aug 2010

XOMA sells royalty interest in CIMZIA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced today that it has sold its royalty interest in CIMZIA® (certolizumab pegol) marketed by UCB S.A. for $4 million to an undisclosed buyer. The manufacture of CIMZIA is covered by a license to XOMA's Bacterial Cell Expression technology.

18 Aug 2010

FDA grants orphan drug designation to NephRx's lead product NX001

NephRx Corporation today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function in renal transplant recipients. NX001 is a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure.

18 Aug 2010

USPTO grants Neogenix Oncology patent for DNAs encoding novel molecular aspects of NPC-1 antibody

Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 7,763,720, with claims related to DNAs encoding the novel molecular aspects of the Company's NPC-1 antibody.

18 Aug 2010

Advanced Cell Technology to obtain patent for cellular reprogramming, generation of iPS cells

Advanced Cell Technology, Inc. announced today that it is positioned to obtain significant patents relating to cellular reprogramming and the generation of induced pluripotent stem (iPS) cells. iPS cells are similar to embryonic stem (ES) cells, except they are generated from adult cells such as skin using certain reprogramming factors, without the controversial use of embryos. Although human iPS cells were first produced in 2007, ACT has been working on inducing pluripotency, with positive results, for more than a decade. The Company's efforts go back to the 1990s, providing (through existing patent filings and continuations) some of the earliest priority dates in the field.

18 Aug 2010

Luminex donates new MAGPIX system to Papua New Guinea Institute of Medical Research

Luminex Corporation, the worldwide leader in multiplexed solutions, today announced it has donated the first commercial unit of its newly launched MAGPIX® instrument to Professor Peter Siba and his scientific team at the Papua New Guinea Institute of Medical Research. The instrument will be used onsite in Papua New Guinea to progress malaria research led by Dr. Peter Zimmerman, Professor of International Health, Genetics and Biology at the Center for Global Health and Diseases at Case Western Reserve University.

From Luminex 18 Aug 2010

Medtronic to acquire Osteotech for $6.50 per share

Medtronic Inc.,and Osteotech, Inc.,today announced that the companies have signed a definitive agreement under which Medtronic will acquire Osteotech for $6.50 per share in cash for each share of Osteotech common stock. The total value of the transaction is expected to be approximately $123 million.

18 Aug 2010

NCI grants SBIR award to MabVax Therapeutics

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP).

18 Aug 2010

BioMarin Pharmaceutical acquires ZyStor Therapeutics, furthers development of ZC-701 for Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the treatment of lysosomal storage disorders. ZyStor's lead product candidate is ZC-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease.

18 Aug 2010

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.

17 Aug 2010

TRI awarded RSC contract to support domestic, international clinical research programs

Technical Resources International, Inc. is pleased to announce that TRI has been awarded the Regulatory Support Center contract by the U.S. National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health, Department of Health and Human Services.

17 Aug 2010

Tecan, Miltenyi Biotec partner to develop magnetic bead technology based automated solutions for cell biology

Tecan is working with Miltenyi Biotec, a leading provider of cell biology solutions, to develop a range of automated solutions for cell biology, based on the powerful MACS(R) Magnetic bead technology. This new agreement will allow customers to benefit from the advanced capabilities of Tecan's Freedom EVO(R) liquid handling platforms when performing a wide range of separation, cultivation and analysis processes for cells and biomolecules.

From Tecan 17 Aug 2010

Discovery can lead to new class of drugs for chronic pain treatment

Researchers have made a discovery that could lead to a brand new class of drugs to treat chronic pain caused by inflammatory conditions such as arthritis and back pain without numbing the whole body.

17 Aug 2010

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

A protein associated with cancer progression when abundant inside of tumors also unexpectedly regulates the creation of new blood vessels that feed the tumor outside, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the August edition of Cancer Cell.

17 Aug 2010

MMV joins Pool for Open Innovation against neglected tropical diseases

The Medicines for Malaria Venture (MMV) today became the first product development partnership (PDP) to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases. MMV joins GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in contributing to the Pool, which is administered by BIO Ventures for Global Health (BVGH).

17 Aug 2010

Biotechnology News and Research

PharmaVentures announces global expansion of PharmaDeals Agreements

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Cognition Therapeutics receives grant to develop small-molecule drug candidate for Alzheimer's disease

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS

Regenicin acquires worldwide exclusive license to know-how technology

XOMA sells royalty interest in CIMZIA

FDA grants orphan drug designation to NephRx's lead product NX001

USPTO grants Neogenix Oncology patent for DNAs encoding novel molecular aspects of NPC-1 antibody

Advanced Cell Technology to obtain patent for cellular reprogramming, generation of iPS cells

Luminex donates new MAGPIX system to Papua New Guinea Institute of Medical Research

Medtronic to acquire Osteotech for $6.50 per share

NCI grants SBIR award to MabVax Therapeutics

BioMarin Pharmaceutical acquires ZyStor Therapeutics, furthers development of ZC-701 for Pompe disease

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

TRI awarded RSC contract to support domestic, international clinical research programs

Tecan, Miltenyi Biotec partner to develop magnetic bead technology based automated solutions for cell biology

Discovery can lead to new class of drugs for chronic pain treatment

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

MMV joins Pool for Open Innovation against neglected tropical diseases

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News